Insulin Postconditioning Reduces Infarct Size in the Porcine Heart in a Dose-Dependent Manner

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 22, Issue 2, 2017, Pages 179-188

  Slettom, Grete ^a,b   Jonassen, Anne K ^b,c   Dahle, Geir O ^b   Seifert, Reinhard ^a   Larsen, Terje H ^a,b   Berge, Rolf K ^b   Nordrehaug, Jan E ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

acute myocardial infarction; apoptosis; heart disease; insulin; ischemia reperfusion injury; swine

Indexed keywords

CARNITINE; CASPASE 3; FATTY ACID; GLUCOSE; NEUTRAL INSULIN; NORMETADRENALIN; POTASSIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HEART RATE; INTRACORONARY DRUG ADMINISTRATION; ISCHEMIC POSTCONDITIONING; NONHUMAN; OPTIMAL DRUG DOSE; PIG;

EID: 85011416516     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248416657611     Document Type: Article

References (45)

1. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33 (20): 2569-2619.
2. Longacre LS, Kloner RA, Arai AE, et al. New horizons in cardioprotection. Circulation. 2011; 124 (10): 1172-1179.
3. Jonassen AK, Aasum E, Riemersma RA, Mjøs OD, Larsen TS,. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther. 2000; 14 (6): 615-623.
4. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 2002; 105 (12): 1497-1502.
5. Zhang HX, Zang YM, Huo JH, et al. Physiologically tolerable insulin reduces myocardial injury and improves cardiac functional recovery in myocardial ischemic/reperfused dogs. J Cardiovasc Pharm. 2006; 48 (6): 306-313.
6. Mamas MA, Neyses L, Fath-Ordoubadi F,. A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol. 2010; 15 (2): e20-e24.
7. Grossman AN, Opie LH, Beshansky JR, Ingwall JS, Rackley CE, Selker HP,. Glucose-insulin-potassium revived: current status in acute coronary syndromes and the energy-depleted heart. Circulation. 2013; 127 (9): 1040-1048.
8. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012; 307 (18): 1925-1939.
9. Howell NJ, Ashrafian H, Drury NE, et al. Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial. Circulation. 2011; 123 (2): 170-177.
10. Angelos MG, Murray HN, Gorsline RT, Klawitter PF,. Glucose, insulin and potassium (GIK) during reperfusion mediates improved myocardial bioenergetics. Resuscitation. 2002; 55 (3): 329-336.
11. Jonassen AK, Sack MN, Mjøs OD, Yellon DM,. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001; 89 (12): 1191-1198.
12. Slettom G, Jonassen AK, Tuseth V, et al. Percutaneous catheter-based intracoronary infusion of insulin-a dose finding study in the porcine model. Basic Clin Pharmacol Toxicol. 2011; 108 (6): 414-420.
13. Helgeland E, Guvag S, Jonassen AK,. Insulin induced cytoprotection by mimicking postconditioning at myocardial reperfusion. Mol Cell Cardiol. 2007; 42 (6): 185-186.
14. Slettom G, Jonassen AK, Breivik L, Seifert R, Nordrehaug JE,. Influence of feeding and intracoronary dose on insulin-mediated relative akt phosphorylation in the porcine myocardium. Cardiovasc Ther. 2013; 31 (6): 125-132.
15. Sörensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart. 2010; 96 (21): 1710-1715.
16. Timmer JR, van der Horst IC, Ottervanger JP, et al. Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. Am Heart J. 2004; 148 (3): 399-404.
17. Crick SJ, Sheppard MN, Ho SY, Gebstein L, Anderson RH,. Anatomy of the pig heart: comparisons with normal human cardiac structure. J Anat. 1998; 193 (pt 1): 105-119.
18. Götberg M, Olivecrona GK, Engblom H, et al. Rapid short-duration hypothermia with cold saline and endovascular cooling before reperfusion reduces microvascular obstruction and myocardial infarct size. BMC Cardiovasc Disord. 2008; 8: 7.
19. Heiberg E, Sjögren J, Ugander M, Carlsson M, Engblom H, Arheden H,. Design and validation of segment-freely available software for cardiovascular image analysis. BMC Med Imaging. 2010; 10: 1.
20. Vigerust NF, Bohov P, Bjørndal B, et al. Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. Fertil Steril. 2012; 98 (6): 1620-1626.
21. Skyschally A, Schulz R, Heusch G,. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther. 2010; 24 (1): 85-87.
22. Musiolik J, van Caster P, Skyschally A, et al. Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Cardiovasc Res. 2010; 85 (1): 110-117.
23. Skyschally A, van Caster P, Boengler K, et al. Ischemic postconditioning in pigs no causal role for RISK activation. Circ Res. 2009; 104 (1): 15-35.
24. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53 (6): 501-510.
25. Lie RH, Stoettrup E, Sloth E, Hasenkam JM, Kroyer R, Nielsen TT,. Post-conditioning with cyclosporine A fails to reduce the infarct size in an in vivo porcine model. Acta Anaesthesiol Scand. 2010; 54 (7): 804-813.
26. Lønborg J, Kelbæk H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interven. 2010; 3 (1): 34-41.
27. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999; 100 (19): 1992-2002.
28. Birnbaum Y, Hale SL, Kloner RA,. Differences in reperfusion length following 30 minutes of ischemia in the rabbit influence infarct size, as measured by triphenyltetrazolium chloride staining. J Mol Cell Cardiol. 1997; 29 (2): 657-666.
29. Ubachs JF, Engblom H, Koul S, et al. Myocardium at risk can be determined by ex vivo T2-weighted magnetic resonance imaging even in the presence of gadolinium: comparison to myocardial perfusion single photon emission computer tomography. Eur Heart J Cardiovasc Imaging. 2013; 14 (3): 261-268.
30. Hallén J, Buser P, Schwitter J, et al. Relation of cardiac troponin I measurements at 24 and 48 hours to magnetic resonance-determined infarct size in patients with ST-elevation myocardial infarction. Am J Cardiol. 2009; 104 (11): 1472-1477.
31. Mayr A, Klug G, Schocke M, et al. Late microvascular obstruction after acute myocardial infarction: relation with cardiac and inflammatory markers. Int J Cardiol. 2012; 157 (3): 391-396.
32. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008; 359 (5): 473-481.
33. Fujiwara H, Matsuda M, Fujiwara Y, et al. Infarct size and the protection of ischemic myocardium in pig, dog and human. Jpn Circ J. 1989; 53 (9): 1092-1097.
34. Swaanenburg JC, Visser-VanBrummen PJ, DeJongste MJ, Tiebosch AT,. The content and distribution of troponin I, troponin T, myoglobin, and alpha-hydroxybutyric acid dehydrogenase in the human heart. Am J Clin Pathol. 2001; 115 (5): 770-777.
35. Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA,. PKB and the mitochondria: AKTing on apoptosis. Cell Signal. 2008; 20 (1): 21-30.
36. Salminen PR, Dahle GO, Moen CA, et al. Reperfusion therapy with low-dose insulin or insulin-like growth factor 2; myocardial function and infarct size in a porcine model of ischaemia and reperfusion. Basic Clin Pharmacol Toxicol. 2014; 115 (5): 438-447.
37. Verma S, Fedak P, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002; 105 (20): 2332-2336.
38. Zhu P, Lu L, Xu Y, Greyson C, Schwartz GG,. Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2000; 278 (2): H595-H603.
39. Schneider CA, Taegtmeyer H,. Fasting in vivo delays myocardial cell damage after brief periods of ischemia in the isolated working rat heart. Circ Res. 1991; 68 (4): 1045-1050.
40. Liepinsh E, Makrecka M, Kuka J, et al. The heart is better protected against myocardial infarction in the fed state compared to the fasted state. Metabolism. 2014; 63 (1): 127-136.
41. Yu Q, Zhou N, Nan Y, et al. Effective glycaemic control critically determines insulin cardioprotection against ischaemia/reperfusion injury in anaesthetized dogs. Cardiovasc Res. 2014; 103 (2): 238-247.
42. Xue YZ, Wang LX, Liu HZ, Qi XW, Wang XH, Ren HZ,. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2007; 21 (6): 445-448.
43. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S,. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. Cardiology. 2006; 106 (4): 215-223.
44. Yu Q, Gao F, Ma XL,. Insulin says NO to cardiovascular disease. Cardiovasc Res. 2011; 89 (3): 516-524.
45. Lønborg J, Kelbæk H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Eur Heart J. 2012: 33 (12): 1491-1499.